Artimplant issues new stock

Press Release

Västra Frölunda, Sweden, August 3, 2010

· The Board of Directors has decided to propose at an extraordinary
meeting of the stockholders that a rights issue be implemented which is
expected to generate capital input for the Company of approximately SEK
40 million after issue costs.

· The main purpose of the new stock issue is to generate the financial
capacity to:

· expand own sales in the USA and
· implement a restructuring process that will result in a significant
reduction in costs not related directly to marketing and sales in
Artimplant AB.

· It is the ambition of the Board of Directors that the majority of
the issue will be secured through declarations of intent and guarantee
undertakings.

· Subscription commitments and guarantee undertakings from the Board
of Directors and senior management total just over SEK 5 million.

· The subscription price and subscription ratio will be announced on
September 14, 2010.

· The subscription period will be September 27 - October 11, 2010.

· An extraordinary meeting of the stockholders will be held on
September 6, 2010 to decide on the proposed issue.

The Board of Directors of Artimplant has decided today to propose at an
extraordinary meeting of the stockholders that a rights issue be
implemented which is expected to generate capital input for the Company
of approximately SEK 40 million after issue costs.

The main purpose of the new stock issue is to generate the financial
capacity to: (i) increase own sales in the USA by expanding the sales
organization, intensify marketing, broaden the product range and conduct
sales-supporting clinical studies as well as (ii) implement a
restructuring that will result in a significant reduction in costs at
Artimplant AB. The planned activities are a result of a decision by the
Board of Directors to make Artimplant's strategy even more market
oriented. The decision does not affect the Company's ambitious plans for
existing development projects or undertakings in clinical studies.

It is proposed that stockholders have an option right to subscribe for
new stocks in relation to the number of stocks they already hold.
Holders of Series A stocks and Series B stocks will be offered the
opportunity to subscribe for Series B stocks. It will also be possible
to subscribe for stocks without an option right. It is proposed that the
Board of Directors, or the person appointed by the Board of Directors
from within its number, be authorized to decide on the amount by which
Artimplant AB's capital stock will be increased, the number of shares
that will be issued and the amount that will be paid for each new share.
A decision on the increase in capital stock, the number of stocks that
will be issued and the subscription price for the new stocks is expected
to be reached by the Board of Directors on September 14, 2010.

An extraordinary meeting of the stockholders will be held to decide on
the proposed issue. The meeting will take place at 9 am on September 6,
2010 at the Company's premises at Hulda Mellgrens gata 5, Västra
Frölunda. The summons to the extraordinary meeting of the stockholders
will be published along with this press release on August 6 in Dagens
Industri and Post och Inrikes Tidningar and will be available together
with other documents at
www.artimplant.com/investors-media/corporate-governance.html (http://www
.artimplant.com/investors-media/corporate-governance.html).

Preliminary time schedule for the rights issue

September 6, 2010 A decision will be reached
at an extraordinary meeting of the stockholders regarding an amendment
to the Articles of Association and the new issue and the Board of
Directors will be authorized to stipulate the final terms and conditions
for the new issue.

September 14, 2010 The subscription price and
subscription ratio will be announced.

September 17, 2010 The final date for trading in
the stocks with an option right to participate in the new issue.

September 21, 2010 The estimated date for
publication of a prospectus.

September 22, 2010 The record date at Euroclear
Sweden AB (previously VPC) for participation in the new issue.
Stockholders who are registered in the stockholders' register on this
date will receive subscription rights.

September 27 - October 7, 2010 Trading in subscription rights.

September 27 - October 11, 2010 Subscription period.

October 12, 2010 Publication of the
preliminary outcome.

Financial and legal advisers

Avanza Bank AB is the financial adviser and Advokatfirman Vinge is the
legal adviser.

For further information, please contact:

Ingemar Kihlström, Chairman, phone +46 (0)733-82 11 02

Hans Rosén, CEO, phone 46 (0)31-746 56 00, 46 (0)708 58 34 70,
hans.rosen@artimplant.com (hans.rosen@artimplant.com)

Lars-Johan Cederbrant, CFO, phone 46 (0)31-746 56 54, 46 (0)703 01 68
54,
lars-johan.cederbrant@artimplant.com (lars-johan.cederbrant@artimplant.c
om)

Further information is available at
www.artimplant.com (http://www.artimplant.com). To subscribe to future
press releases please go to
www.artimplant.com/investors-media/subscribe-to-press-releases.html (htt
p://www.artimplant.com/investors-media/subscribe-to-press-releases.html)

Artimplant issues new stock

Attachments